A newly published expert paper in JAMA is adding to the growing body of evidence supporting nicotine e-cigarettes as a smoking cessation option for adults. While the publication is not a new clinical trial or an official U.S. treatment guideline, it represents the consensus of an international panel of tobacco harm reduction researchers and clinicians who believe nicotine e-cigarettes deserve a place alongside traditional quit-smoking therapies.  

For manufacturers, distributors, retailers, and the broader nicotine industry, the paper signals an important shift in how vaping products are being discussed within the medical community. 

 

A New Clinical Perspective 

The expert workgroup recommends that healthcare providers discuss nicotine e-cigarettes as one of several evidence-based options available to adults who want to quit smoking. Rather than requiring smokers to first fail nicotine replacement therapy (NRT) or prescription medications, the paper suggests clinicians should consider patient preferences and previous quit attempts when recommending cessation strategies.  

The recommendations are based on a review of existing research, including systematic reviews that found nicotine e-cigarettes produced higher quit rates than traditional nicotine replacement therapies such as patches and gum, with results comparable to some of the most effective prescription smoking cessation medications.  

 

Complete Switching Remains the Goal 

One of the paper's strongest messages is that vaping should not be viewed as a permanent substitute for cigarettes through prolonged dual use. 

Instead, researchers emphasize that adult smokers should work toward completely replacing combustible cigarettes, with dual use serving only as a temporary transition. The greatest reductions in exposure to harmful toxicants occur when cigarettes are eliminated entirely.  

The paper also notes that behavioral counseling and ongoing support remain important parts of any quit attempt, regardless of which cessation method is chosen.  

 

Product Performance Matters 

Beyond clinical recommendations, the publication highlights something the vapor industry has long recognized: products must actually satisfy adult smokers if they are expected to replace cigarettes. 

Researchers conclude that effective products must: 

• Deliver nicotine efficiently enough to relieve cravings.  

• Provide sufficient satisfaction to replace smoking.  

• Minimize the need for compensatory vaping.  

• Help adult smokers transition away from combustible cigarettes.  

The paper cautions that products delivering insufficient nicotine may actually reduce cessation success by encouraging users to vape more frequently without adequately replacing cigarettes.  

 

Implications for Manufacturers 

For product developers, the report suggests that future innovation should focus on more than emissions testing or laboratory performance. 

Manufacturers should continue investing in products that can: 

• Deliver consistent nicotine levels.  

• Provide a satisfying user experience.  

• Reduce withdrawal symptoms.  

• Encourage complete switching.  

• Lower relapse rates.  

According to the authors, real-world effectiveness in helping adult smokers quit combustible cigarettes should remain a central objective for product development.  

 

A Challenge for Regulators 

The publication also raises broader policy questions. 

The authors argue that regulations affecting nicotine delivery, flavors, or overall product experience should carefully balance two public health goals: 

• Preventing youth initiation.  

• Preserving products that are effective enough to help adult smokers transition away from combustible cigarettes.  

Policies that unintentionally reduce product satisfaction or nicotine delivery could make complete switching more difficult for adults attempting to quit smoking.  

 

The Bottom Line 

Although this publication does not change U.S. clinical guidelines or FDA policy, it represents another significant step in the evolving conversation around tobacco harm reduction. 

An international panel of experts has concluded that nicotine e-cigarettes should be part of smoking cessation discussions for adult smokers and that products capable of effectively replacing combustible cigarettes deserve consideration alongside traditional cessation therapies. 

For the vapor industry, the paper reinforces an important principle: product quality, nicotine delivery, and user satisfaction are not simply commercial features—they are central to whether adult smokers can successfully make the switch away from cigarettes.